DOP2019000126A - Pirrolopirimidinas como potenciadores de cftr - Google Patents
Pirrolopirimidinas como potenciadores de cftrInfo
- Publication number
- DOP2019000126A DOP2019000126A DO2019000126A DO2019000126A DOP2019000126A DO P2019000126 A DOP2019000126 A DO P2019000126A DO 2019000126 A DO2019000126 A DO 2019000126A DO 2019000126 A DO2019000126 A DO 2019000126A DO P2019000126 A DOP2019000126 A DO P2019000126A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cftr
- compounds
- cystic fibrosis
- pyrrolopyrimidines
- potentials
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423919P | 2016-11-18 | 2016-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000126A true DOP2019000126A (es) | 2019-08-30 |
Family
ID=62144793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000126A DOP2019000126A (es) | 2016-11-18 | 2019-05-17 | Pirrolopirimidinas como potenciadores de cftr |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10301315B2 (OSRAM) |
| EP (2) | EP4424311A3 (OSRAM) |
| JP (3) | JP6978507B2 (OSRAM) |
| KR (2) | KR102824092B1 (OSRAM) |
| CN (2) | CN115850268B (OSRAM) |
| AU (2) | AU2017362350B2 (OSRAM) |
| CA (1) | CA3044050A1 (OSRAM) |
| CL (1) | CL2019001334A1 (OSRAM) |
| CO (1) | CO2019005993A2 (OSRAM) |
| CR (1) | CR20190292A (OSRAM) |
| DO (1) | DOP2019000126A (OSRAM) |
| EC (1) | ECSP19043120A (OSRAM) |
| ES (1) | ES2983686T3 (OSRAM) |
| IL (3) | IL296279A (OSRAM) |
| MX (2) | MX387203B (OSRAM) |
| PE (1) | PE20200739A1 (OSRAM) |
| PH (1) | PH12019501098A1 (OSRAM) |
| PL (1) | PL3541390T3 (OSRAM) |
| RU (2) | RU2021129721A (OSRAM) |
| SG (1) | SG10202106949XA (OSRAM) |
| UA (1) | UA125400C2 (OSRAM) |
| WO (1) | WO2018094137A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508407A (ja) | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| RS60906B1 (sr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| AU2016379388A1 (en) * | 2015-12-22 | 2018-07-12 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| HUE056716T2 (hu) | 2016-09-30 | 2022-03-28 | Vertex Pharma | Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására |
| WO2018094137A1 (en) * | 2016-11-18 | 2018-05-24 | Cystic Fibrosis Foundation Therapeutics Inc. | Pyrrolopyrimidines as cftr potentiators |
| EP3812379A1 (en) | 2016-12-09 | 2021-04-28 | Vertex Pharmaceuticals Incorporated | Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis |
| RU2753056C2 (ru) | 2016-12-16 | 2021-08-11 | Систик Файбросис Фаундейшн | Бициклические гетероарильные производные в качестве стимуляторов cftr |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| JP7245834B2 (ja) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| LT3752510T (lt) | 2018-02-15 | 2023-04-11 | Vertex Pharmaceuticals Incorporated | Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| KR20220019015A (ko) * | 2019-06-10 | 2022-02-15 | 노파르티스 아게 | Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체 |
| JP2022541178A (ja) | 2019-07-15 | 2022-09-22 | ノバルティス アーゲー | （ｓ）－３－アミノ－６－メトキシ－ｎ－（３，３，３－トリフルオロ－２－ヒドロキシ－２－メチルプロピル）－５－（トリフルオロメチル）ピコリンアミド製剤 |
| WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| EP4013741B1 (en) | 2019-08-14 | 2024-04-17 | Vertex Pharmaceuticals Incorporated | Process of making cftr modulators |
| CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
| WO2021176049A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| EP4199914A4 (en) | 2020-08-20 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATMENT OF RESPIRATORY DISEASES CHARACTERIZED BY HYPERSECRETION OF MUCUS |
| KR20230118123A (ko) | 2020-12-10 | 2023-08-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| TW202425990A (zh) * | 2022-11-02 | 2024-07-01 | 南韓商日東製藥股份有限公司 | 包含ｃｆｔｒ調節劑化合物之點眼用組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2128544T3 (es) * | 1992-12-17 | 1999-05-16 | Pfizer | Pirrolopirimidinas como antagonistas del crf. |
| NZ518726A (en) * | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| JP2004534779A (ja) * | 2001-05-30 | 2004-11-18 | エルジー ライフサイエンス リミテッド | 疾病治療用プロテインキナーゼ阻害剤 |
| US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| TW201307354A (zh) * | 2005-12-29 | 2013-02-16 | Abbott Lab | 蛋白質激酶抑制劑 |
| ATE531718T1 (de) * | 2006-03-11 | 2011-11-15 | Vernalis R&D Ltd | Als hsp90-inhibitoren verwendete pyrrolopyrimidinderivate |
| KR20090017498A (ko) * | 2006-04-04 | 2009-02-18 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | Ｐｉ３ 키나제 길항물질 |
| JP2011503103A (ja) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
| CA2749228C (en) * | 2009-01-08 | 2016-05-17 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| US20130123281A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
| US8828998B2 (en) * | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2015091532A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
| WO2018094137A1 (en) * | 2016-11-18 | 2018-05-24 | Cystic Fibrosis Foundation Therapeutics Inc. | Pyrrolopyrimidines as cftr potentiators |
-
2017
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en not_active Ceased
- 2017-11-17 KR KR1020237033420A patent/KR102824092B1/ko active Active
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/ja active Active
- 2017-11-17 UA UAA201906838A patent/UA125400C2/uk unknown
- 2017-11-17 MX MX2019005822A patent/MX387203B/es unknown
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/ru unknown
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/es unknown
- 2017-11-17 CN CN202211239693.0A patent/CN115850268B/zh active Active
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 EP EP24170395.8A patent/EP4424311A3/en active Pending
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 CA CA3044050A patent/CA3044050A1/en active Pending
- 2017-11-17 ES ES17872726T patent/ES2983686T3/es active Active
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/ru active
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/zh active Active
- 2017-11-17 CR CR20190292A patent/CR20190292A/es unknown
- 2017-11-17 IL IL314404A patent/IL314404B1/en unknown
- 2017-11-17 PL PL17872726.9T patent/PL3541390T3/pl unknown
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/ko active Active
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/es unknown
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/es unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/es unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/es unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/es unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US20230250100A1/en active Pending
- 2023-09-29 JP JP2023169299A patent/JP7592814B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19043120A (es) | Pirrolopirimidinas como potenciadores de cftr | |
| MX2019007135A (es) | Derivados de heteroarilo biciclico como potenciadores de cftr. | |
| CU20120139A7 (es) | Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf) | |
| DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
| BR112018007161A2 (pt) | pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| BR112018007145A2 (pt) | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso | |
| UY40365A (es) | Cromanos sustituidos y sales farmacéuticamente aceptables de los mismos, y composiciones que los comprenden | |
| BR112018072047A2 (pt) | moduladores da proteína reguladora de condutância transmembranar de fibrose cística | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| PA8774101A1 (es) | Compuesto de pirmidina | |
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CL2014000122A1 (es) | Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. | |
| BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
| CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
| CO6640319A2 (es) | Formulación en polvo seca que comprende una droga antimuscarínica | |
| SV2009002861A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| EA202092976A1 (ru) | Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| UY30934A1 (es) | Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones. | |
| PT115583A (pt) | Processo contínuo para a preparação de medicamentos anticolinérgicos |